These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9179228)

  • 1. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.
    Denardo SJ; O'Grady LF; Richman CM; Goldstein DS; O'Donnell RT; Denardo DA; Kroger LA; Lamborn KR; Hellström KE; Hellström I; Denardo GL
    Anticancer Res; 1997; 17(3B):1745-51. PubMed ID: 9179228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions.
    Richman CM; DeNardo SJ; O'Grady LF; DeNardo GL
    Cancer Res; 1995 Dec; 55(23 Suppl):5916s-5920s. PubMed ID: 7493370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biologic window for chimeric L6 radioimmunotherapy.
    DeNardo SJ; Mirick GR; Kroger LA; O'Grady LF; Erickson KL; Yuan A; Lamborn KR; Hellstrom I; Hellstrom KE; DeNardo GL
    Cancer; 1994 Feb; 73(3 Suppl):1023-32. PubMed ID: 8306244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.
    Leigh BR; Burke PA; Hong AM; O'Donnell RT; Howell LP; Miers LA; DeNardo GL; DeNardo SJ
    Cancer Biother Radiopharm; 1999 Apr; 14(2):113-9. PubMed ID: 10850294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6.
    DeNardo SJ; O'Grady LF; Richman CM; DeNardo GL
    Adv Exp Med Biol; 1994; 353():203-11. PubMed ID: 7527179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ; Richman CM; Goldstein DS; Shen S; Salako Q; Kukis DL; Meares CF; Yuan A; Welborn JL; Denardo GL
    Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.
    Govindan SV; Stein R; Qu Z; Chen S; Andrews P; Ma H; Hansen HJ; Griffiths GL; Horak ID; Goldenberg DM
    Breast Cancer Res Treat; 2004 Mar; 84(2):173-82. PubMed ID: 14999147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
    DeNardo SJ; Gumerlock PH; Winthrop MD; Mack PC; Chi SG; Lamborn KR; Shen S; Miers LA; deVere White RW; DeNardo GL
    Cancer Res; 1995 Dec; 55(23 Suppl):5837s-5841s. PubMed ID: 7493356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
    Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
    J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer.
    Shih LB; Xuan H; Aninipot R; Stein R; Goldenberg DM
    Cancer Res; 1995 Dec; 55(23 Suppl):5857s-5863s. PubMed ID: 7493360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
    Behr TM; Sharkey RM; Juweid ME; Dunn RM; Ying Z; Zhang CH; Siegel JA; Goldenberg DM
    J Nucl Med; 1997 Mar; 38(3):409-18. PubMed ID: 9074529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods.
    Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Hasan ZM; Salouti M; Gandomkar M; Sadri K
    Hum Antibodies; 2010; 19(1):15-25. PubMed ID: 20555127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
    Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
    Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
    Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
    Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
    J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials.
    Chen ZN; Mi L; Xu J; Song F; Zhang Q; Zhang Z; Xing JL; Bian HJ; Jiang JL; Wang XH; Shang P; Qian AR; Zhang SH; Li L; Li Y; Feng Q; Yu XL; Feng Y; Yang XM; Tian R; Wu ZB; Leng N; Mo TS; Kuang AR; Tan TZ; Li YC; Liang DR; Lu WS; Miao J; Xu GH; Zhang ZH; Nan KJ; Han J; Liu QG; Zhang HX; Zhu P
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):435-44. PubMed ID: 16690431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments.
    Behr TM; Blumenthal RD; Memtsoudis S; Sharkey RM; Gratz S; Becker W; Goldenberg DM
    Clin Cancer Res; 2000 Dec; 6(12):4900-7. PubMed ID: 11156250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.